We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

69 hedge funds and large institutions have $372M invested in Aimmune Therapeutics in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

180% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 10

19% more funds holding

Funds holding: 58 → 69 (+11)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

22% less capital invested

Capital invested by funds: $476M → $372M (-$103M)

Holders
69
Holders Change
+11
Holders Change %
+18.97%
% of All Funds
1.84%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
17
Increased
28
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
+$14.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$8.32M
3
EC
EcoR1 Capital
California
+$8.13M
4
RCM
RA Capital Management
Massachusetts
+$7.84M
5
Bank of America
Bank of America
North Carolina
+$2.03M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$18.4M
2
NI
Numeric Investors
Massachusetts
-$642K
3
AllianceBernstein
AllianceBernstein
Tennessee
-$594K
4
FAM
Fred Alger Management
New York
-$318K
5
TCIM
TIAA CREF Investment Management
New York
-$268K
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$1.27M +$60.1K +3,855 +4%
Wells Fargo
27
Wells Fargo
California
$741K +$749K +47,985 +715%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$697K +$107K +6,867 +15%
Federated Hermes
29
Federated Hermes
Pennsylvania
$678K – – –
AA
30
ALPS Advisors
Colorado
$644K -$127K -8,143 -15%
JP Morgan Chase
31
JP Morgan Chase
New York
$574K +$660K +42,300 New
PPA
32
Parametric Portfolio Associates
Washington
$530K +$356K +22,837 +140%
BIM
33
BlackRock Investment Management
Delaware
$523K +$15.4K +988 +3%
TCIM
34
TIAA CREF Investment Management
New York
$455K -$268K -17,210 -34%
Charles Schwab
35
Charles Schwab
California
$363K +$7.16K +459 +2%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$319K +$46.3K +2,967 +14%
TC
37
TFS Capital
Pennsylvania
$316K +$364K +23,302 New
Morgan Stanley
38
Morgan Stanley
New York
$307K +$278K +17,812 +369%
Swiss National Bank
39
Swiss National Bank
Switzerland
$292K +$140K +8,974 +67%
CS
40
Credit Suisse
Switzerland
$255K +$293K +18,775 New
DTL
41
Dynamic Technology Lab
Singapore
$229K +$263K +16,873 New
TA
42
Teachers Advisors
New York
$227K – – –
Goldman Sachs
43
Goldman Sachs
New York
$212K +$244K +15,639 New
HCM
44
Highbridge Capital Management
New York
$188K +$215K +13,795 New
VEA
45
Virtus ETF Advisers
New York
$185K +$213K +13,666 New
TD Asset Management
46
TD Asset Management
Ontario, Canada
$180K -$15.6K -1,000 -7%
RJA
47
Raymond James & Associates
Florida
$168K +$193K +12,356 New
LCM
48
Laurion Capital Management
New York
$149K +$172K +11,000 New
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$145K – – –
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$145K +$167K +10,680 New
1
2
3

AIMT Hedge Fund Activity: Q1 2016 in Review

69 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q1 2016, worth a combined $372M — down 22% from $476M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new AIMT positions and 6 closed out — a net gain of 11 holders — while 28 added to existing stakes and 10 trimmed.

The largest buyer was Eagle Asset Management, adding an estimated $14.1M. The largest seller was Fidelity Investments, cutting an estimated $18.4M.

  • 69 institutional investors held Aimmune Therapeutics (AIMT) as of Q1 2016, up from 58 in Q4 2015.
  • Funds reported $372M of Aimmune Therapeutics stock for Q1 2016, down 22% quarter-over-quarter.
  • 17 funds opened new Aimmune Therapeutics positions in Q1 2016 and 6 closed out, a net change of +11 holders.
  • The largest Aimmune Therapeutics buyer in Q1 2016 was Eagle Asset Management, an estimated $14.1M added.
  • The largest Aimmune Therapeutics seller in Q1 2016 was Fidelity Investments, an estimated $18.4M sold.

Based on aggregated 13F filings for Q1 2016.